Maiden Pharma may lose import-export licence over cough syrup controversy in Gambia

Monday, 10 October 2022

Maiden Pharma may lose import-export licence over cough syrup controversy in Gambia

The suspension of membership implies that Maiden Pharmaceuticals will not be eligible to receive any incentives.

0 shares	Share Tweet Save Post Send

Shocked to hear... Maiden Pharma breaks silence on cough syrup deaths in Gambia

newKerala.com on October 9, 2022

Haryana STOPS cough syrup production by Maiden Pharma linked to 66 child deaths in Gambia

Earlier on Monday, the Indian Pharma company had released a statement over the reports linking its cough syrups to the deaths of 66 children in Gambia.
Zee News on October 12, 2022 Also reported by •DNA

Maiden Pharma may lose import-export licence over cough syrup controversy in Gambia

You Might Like

Related news from verified sources

Shocked to hear... Maiden Pharma breaks silence on cough syrup deaths in Gambia

Haryana STOPS cough syrup production by Maiden Pharma linked to 66 child deaths in Gambia